Curis, Inc. (NASDAQ:CRIS), announced that it has commenced an underwritten public offering of shares of its common stock.
In a research report sent to investors, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Curis Inc. (NASDAQ:CRIS) with a $6.
Curis Inc. (NASDAQ:CRIS) announced a collaboration, license and option agreement with Aurigene focused on the development of small molecule inhibitors of immuno-oncology and …
In a research report sent to investors, Cowen analyst Boris Peaker reiterated an Outperform rating on Curis Inc. (NASDAQ:CRIS), following the news that …
Roth Capital analyst Joseph Pantginis maintained a Buy rating on Curis Inc. (NASDAQ:CRIS) with a price target of $10, as the company announced dosing …
In a research report issued today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Curis Inc. (NASDAQ:CRIS) with a price target …
In a research report published yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Curis Inc. (NASDAQ:CRIS) with a $10 price target, as …
